Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
Status:
Completed
Trial end date:
2015-05-31
Target enrollment:
Participant gender:
Summary
The participants included in this observational study will be drawn from a research database
containing claims and enrollment data for members of a large, geographically diverse US
health plan.The objective of this study is to estimate the rate of serious infections,
tuberculosis, malignancies, and other outcomes in rheumatoid arthritis, psoriatic arthritis,
and ankylosing spondylitis patients treated with golimumab, anti-tumor necrosis factor (TNF)
biologics, non-anti-TNF biologics, or systemic non-biological treatments.